These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 12476281)

  • 1. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS; Greer JP; Goodman S; Brandt SJ; Morgan DS; Macon WR; McCurley TL; Wolff SN
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point.
    Bolwell B; Goormastic M; Andresen S
    Bone Marrow Transplant; 1997 Mar; 19(5):443-8. PubMed ID: 9052909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
    Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
    Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.